We found a similar association between incidence of germline CHEK2 mutations and worse relapse-free survival in patients with primary ER+/HER2− breast cancer in METABRIC (HR = 6.15, P = 0.01) (Fig. 8A). Here, CHEK2 is linked to breast carcinoma.